Research Evidence
Selank's evidence base is unusual among peptides in the nootropic and anxiolytic space: it includes actual clinical trials in human patients, albeit conducted primarily within the Russian clinical research system. The compound also has an extensive preclinical dataset spanning anxiety, cognition, and immune function.
Clinical Trial: Selank vs. Medazepam in GAD
The foundational clinical study enrolled 62 patients with generalized anxiety disorder and neurasthenia, comparing Selank (30 patients) to the benzodiazepine medazepam (32 patients). Both drugs produced comparable anxiolytic effects as measured by the Hamilton Anxiety Rating Scale, Zung Self-Rating Anxiety Scale, and Clinical Global Impression scale. However, Selank additionally demonstrated antiasthenic and psychostimulant properties not seen with medazepam. Critically, Selank treatment correlated with increases in leu-enkephalin levels, a neurochemical change linked to improved anxiety scores and absent in the benzodiazepine group.
Clinical Trial: Selank vs. Phenazepam
A second clinical comparison evaluated Selank against phenazepam (a potent benzodiazepine widely prescribed in Russia) in patients with anxiety disorders. Selank again demonstrated comparable anxiolytic efficacy without the sedation, muscle relaxation, tolerance development, or withdrawal syndrome characteristic of phenazepam. This study strengthened the clinical case for Selank as a benzodiazepine alternative with a superior tolerability profile.
Preclinical: GABAergic Gene Expression
A 2016 study published in Frontiers in Pharmacology examined gene expression changes following Selank administration, finding significant alterations in genes encoding GABA-A receptor subunits and GABA transporters. These changes were rapid (detectable within hours), supporting the mechanism of allosteric GABA-A modulation. A follow-up study in IMR-32 neuroblastoma cells confirmed that Selank's effects on GABAergic gene expression were distinct from those produced by GABA itself or the antipsychotic olanzapine.
Preclinical: Synergy With Diazepam
Research published in Behavioural Neurology demonstrated that Selank enhanced the anxiolytic effects of diazepam in rats subjected to unpredictable chronic mild stress. The combination produced greater anxiety reduction than either compound alone, suggesting that Selank's mechanism is complementary to, rather than redundant with, classical benzodiazepine action.
Preclinical: Immune and Inflammatory Gene Expression
Studies examining Selank's effects on inflammation-related gene expression in mouse spleen tissue found significant changes in 34 of 84 genes analyzed, spanning chemokines, cytokines, and their receptors. A temporal dynamics study revealed that these gene expression changes followed a biphasic pattern, with early pro-inflammatory gene activation followed by later anti-inflammatory gene upregulation, consistent with an immunomodulatory rather than immunosuppressive profile.
Limitations of the Evidence Base
The honest assessment of Selank's evidence is that it is stronger than most peptides in the nootropic space but weaker than established Western pharmaceuticals for anxiety. Key limitations include: clinical trials were conducted in Russia with limited sample sizes and have not been independently replicated in Western research settings; most published studies are in Russian-language journals with limited international peer review; long-term safety data beyond 14-day courses is sparse; and placebo-controlled, double-blind methodology is not consistently documented across all studies.